<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782544</url>
  </required_header>
  <id_info>
    <org_study_id>200109</org_study_id>
    <nct_id>NCT04782544</nct_id>
  </id_info>
  <brief_title>Ganglioside and IBD</brief_title>
  <official_title>Assessing Whether Buttermilk Powder Improves Disease Activity in Pediatric IBD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Orange County</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Orange County</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Context. Inflammatory bowel disease (IBD) is a chronic and debilitating disorder. Novel&#xD;
      treatment strategies aimed to resolve intestinal inflammation and induce disease remission&#xD;
      are necessary. Dietary gangliosides are safe for consumption, bioavailable, and have shown&#xD;
      clinical benefit in patients with inflammatory intestinal disease.&#xD;
&#xD;
      Objectives. The primary objective is this study is to determine the efficacy of dietary&#xD;
      ganglioside in improving disease activity indices in pediatric patients with IBD. Secondary&#xD;
      objectives include demonstrating the effectiveness of dietary ganglioside for improving&#xD;
      quality of life, improving intestinal integrity, and reducing inflammation.&#xD;
&#xD;
      Study Design. Intervention: controlled trial (pilot). Participants. Inclusion criteria: aged&#xD;
      9-21 years, diagnosis of ulcerative colitis (UC) or ileal or colonic Crohn Disease (CD),&#xD;
      active disease. Exclusion criteria: pregnancy, inadequate liver or renal function, active&#xD;
      infectious disease, previous bowel resection, disease remission, drug/alcohol abuse, other&#xD;
      serious medical conditions, indeterminate colitis.&#xD;
&#xD;
      Study Intervention. Patients with IBD (n=48) will be allocated to consume ganglioside&#xD;
      treatment or placebo daily for 10 weeks. Treatment group will consume five grams of&#xD;
      buttermilk powder daily or anhydrous milk fat.&#xD;
&#xD;
      Outcome Measures. The primary outcome is the disease activity index: pediatric Crohn's&#xD;
      Disease Activity Index (pCDAI) or pediatric Ulcerative Colitis Activity Index (pUCAI).&#xD;
      Secondary outcomes include: quality of life (IMPACT-III questionnaire), intestinal&#xD;
      permeability (lactulose/mannitol urinary assay), C-reactive protein (CRP; blood exam),&#xD;
      calprotectin (fecal exam).&#xD;
&#xD;
      Expected Outcomes. Relative to the placebo group, the treatment group will have improved&#xD;
      disease activity indices, quality of life, and intestinal integrity over the 10-week study&#xD;
      period. The treatment group will also show reduction in inflammation and calprotectin&#xD;
      relative to the placebo group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease activity index</measure>
    <time_frame>Day 0</time_frame>
    <description>Pediatric 1) Crohn Disease or 2) Ulcerative Colitis disease activity index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity index</measure>
    <time_frame>Day 70</time_frame>
    <description>Pediatric 1) Crohn Disease or 2) Ulcerative Colitis disease activity index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ImproveCareNow Physician Global Assessment</measure>
    <time_frame>Day 0</time_frame>
    <description>A disease activity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ImproveCareNow Physician Global Assessment</measure>
    <time_frame>Day 70</time_frame>
    <description>A disease activity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IMPACT-III questionnaire</measure>
    <time_frame>Day 0</time_frame>
    <description>quality of life scales (0 = lowest, 100 = highest): well-being, emotional functioning, social functioning, body image</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IMPACT-III questionnaire</measure>
    <time_frame>Day 70</time_frame>
    <description>quality of life scales (0 = lowest, 100 = highest): well-being, emotional functioning, social functioning, body image</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal integrity</measure>
    <time_frame>Day 0</time_frame>
    <description>Intestinal permeability (lactulose/mannitol) challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal integrity</measure>
    <time_frame>Day 70</time_frame>
    <description>Intestinal permeability (lactulose/mannitol) challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>Day 0</time_frame>
    <description>Stool test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>Day 70</time_frame>
    <description>Stool test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Day 70</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hemoglobin, study start</measure>
    <time_frame>Day 0</time_frame>
    <description>g/L, from metabolic panel</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin, study end</measure>
    <time_frame>Day 70</time_frame>
    <description>g/L, from metabolic panel</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelets, study start</measure>
    <time_frame>Day 0</time_frame>
    <description>#, from metabolic panel</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelets, study end</measure>
    <time_frame>Day 70</time_frame>
    <description>#, from metabolic panel</description>
  </other_outcome>
  <other_outcome>
    <measure>White blood cells, study start</measure>
    <time_frame>Day 0</time_frame>
    <description>#, from metabolic panel</description>
  </other_outcome>
  <other_outcome>
    <measure>White blood cells, study end</measure>
    <time_frame>Day 70</time_frame>
    <description>#, from metabolic panel</description>
  </other_outcome>
  <other_outcome>
    <measure>Albumin, study start</measure>
    <time_frame>Day 0</time_frame>
    <description>g/L, from metabolic panel</description>
  </other_outcome>
  <other_outcome>
    <measure>Albumin, study end</measure>
    <time_frame>Day 70</time_frame>
    <description>g/L, from metabolic panel</description>
  </other_outcome>
  <other_outcome>
    <measure>Hematocrit, study start</measure>
    <time_frame>Day 0</time_frame>
    <description>proportion, from metabolic panel</description>
  </other_outcome>
  <other_outcome>
    <measure>Hematocrit, study end</measure>
    <time_frame>Day 70</time_frame>
    <description>proportion, from metabolic panel</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 grams of buttermilk powder daily for 10 weeks, oral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 grams of milk powder (10% buttermilk powder, 90% anhydrous milk fat) daily for 10 weeks, oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Buttermilk Powder</intervention_name>
    <description>Treatment with 5.0 g of buttermilk powder daily for 10 weeks.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anhydrous Milk Fat</intervention_name>
    <description>Treatment with 5.0 g of milk powder (90% anhydrous milk fat, 10% buttermilk powder) daily for 10 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants age 9-21 years&#xD;
&#xD;
          2. Mild-moderate IBD defined by ImproveCareNow (ICN) Physician Global Assessment (PGA);&#xD;
             OR severe IBD defined by ICN PGA if stable for at least 120 days&#xD;
&#xD;
          3. Ileal, ileocolonic, colonic location of disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Previous bowel resection&#xD;
&#xD;
          3. Non-ileocolonic location of disease&#xD;
&#xD;
          4. Inadequate liver or renal function&#xD;
&#xD;
          5. On prescription medication for active infectious disease&#xD;
&#xD;
          6. Drug/alcohol abuse&#xD;
&#xD;
          7. Other serious medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Megan A Bailey</last_name>
    <phone>714-509-8869</phone>
    <email>mebailey@choc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Ornelas</last_name>
      <phone>714-509-8765</phone>
      <email>elisa.ornelas@choc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

